** Shares of Revolution Medicines RVMD.O rise 15% to $123.49 premarket
** Merck MRK.N is in talks to buy Revolution in a deal worth up to $32 bln, FT reported on Thursday
** Analysts see over $10 billion in potential sales from Revolution’s RAS inhibitor portfolio by 2035
** FT report came a day after AbbVie ABBV.N denied a WSJ report that it was in advanced talks to acquire Revolution
** RVMD shares have surged about 34% since the WSJ report, adding about $5.3 billion to its market value, which stood near $20.8 billion, as of last close
** RVMD recently traded at -16.7 times fwd earnings, compared to its five-year avg of -9.8, per LSEG data
** RVMD gained more than 82% in 2025
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Comments